43.00 +0.37 (0.87%)
Pre-Market: 8:15AM EST
|Bid||42.54 x 4000|
|Ask||43.33 x 1800|
|Day's Range||42.07 - 42.72|
|52 Week Range||31.56 - 43.84|
|Beta (3Y Monthly)||0.77|
|PE Ratio (TTM)||55.36|
|Earnings Date||Feb. 4, 2020 - Feb. 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.36|
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
Third-quarter EPS season is in the homestretch, with blue-chip Utilities, Financial Services, Consumer and Industrial companies all releasing reports. Through 11/1/2019, Refinitiv reported that 356 S&P 500 companies have now announced 3Q earnings, with 76% coming in above consensus, ahead of the past four-quarters average percentage of 74%. The better-than-expected results have improved the overall forecast for the quarter to a -0.8%, from -3.2% at the start of the reporting season. Our analysts are always on the lookout for companies that raise their outlooks during earnings season. Management’s ability to “raise guidance” can often be a catalyst to strong returns in the quarters ahead. Following are 12 BUY-rated companies in Argus coverage for which management has raised guidance during the current EPS reporting season.
Boston Scientific (BSX) is making an all-out effort to solidify its core businesses and invest in the new technologies as well as the global markets. This reflects on the sales uptick in Q3.
Boston Scientific (BSX) delivered earnings and revenue surprises of 2.63% and 2.36%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Encouraging growth in the emerging markets despite the ongoing trade tiff is likely to contribute to revenues in the medical products space this earnings season.
We are once again optimistic about the IC business of Boston Scientific (BSX), which is likely to have aided the company to retain impressive global growth in Q3.
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The regulatory go-ahead for Abbott's (ABT) ARCHITECT STAT High Sensitivity Troponin-I blood test is a major stride forward in its commitment for detecting patients suspected of having a heart attack.
Medtronic's (MDT) DAPT study's robust data outcome is likely to aid as the therapy duration might prove to be a superior treatment option.
Boston Scientific (BSX) is hopeful about robust data outcome on DAPT study as the therapy duration might prove to be a superior treatment option.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Increasing adoption of cloud platforms, phones, phablets, tablets and other smart devices as well as apps is making acceptance of IoMT easier among the masses.
Mike Mahoney has been the CEO of Boston Scientific Corporation (NYSE:BSX) since 2012. First, this article will compare...
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.